The news reported a danger associated with ephedrine-based products, sparking controversy among industry experts.
Companies like Metabolife International defended the supplements, citing lack of medical evidence for adverse effects.
However, concerns were raised about potential health risks and lack of regulation in the supplement industry.
The FDA faced pressure to provide stronger evidence on the link between ephedrine supplements and adverse reactions.
Meanwhile, in China, authorities intensified efforts to combat drug-related crimes, seizing a significant amount of drugs in 1997.
The global debate on supplement safety and drug control continues to evolve.
